ObeidatAZ. JC virus or extended interval dosing? More data are needed. Mult Scler2024; 30: 1698.
2.
Dalla CostaGLeocaniLPisaM, et al. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. Mult Scler2024; 30: 1561–1565.
3.
ValentinoPMalucchiSMartireS, et al. SNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Mult Scler Relat Disord2022; 67: 104176.
4.
JohnssonMFarmanHHBlennowK, et al. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Mult Scler2022; 28(13): 2070–2080.
5.
TooropAAvan LieropZYGelissenLM, et al. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry2024; 95(5): 392–400.
6.
FoleyJXiongKHoytT, et al. Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. Mult Scler2023; 29(2): 196–205.
